NR3C2 and diabetic kidney disease: The efficacy of angiotensin II receptor blocker, angiotensin converting enzyme inhibitor and non-steroidal mineralocorticoid receptor antagonist (finerenone) for DKD has been widely confirmed in various large clinical trials so far [130].